Telgio

Telmisartan

Essential HTN. Prevention of CV morbidity & mortality in patients ≥55 yr at high risk of CV disease.

Adult Essential HTN 40 mg once daily, may be increased to max of 80 mg once daily if target BP is not achieved. Patient w/ severe HTN Doses up to 160 mg alone & in combination w/ hydrochlorothiazide 12.5-25 mg daily. Prevention of CV morbidity & mortality 80 mg once daily. Mild to moderate hepatic impairment Do not exceed 40 mg once daily.

May be taken with or without food.

Hypersensitivity. Biliary obstructive disorders. Concomitant use w/ aliskiren in patients w/ DM or renal impairment (GFR <60 mL/min/1.73 m²). Rare hereditary conditions. Severe hepatic impairment. Pregnancy (2nd & 3rd trimesters) & lactation.

Increased risk of severe hypotension & renal insufficiency in patients w/ bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney. Periodic monitoring of K & creatinine serum levels in patients w/ impaired renal function. Patients who are vol- &/or Na-depleted by vigorous diuretic therapy, dietary salt restriction, diarrhea, or vomiting; whose vascular tone & renal function depend predominantly on the activity of the renin-angiotensin-aldosterone system (eg, patients w/ severe CHF or underlying renal disease, including renal artery stenosis). Dual blockade of the renin-angiotensin-aldosterone system. Not recommended in patients w/ primary aldosteronism. Patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy. Monitor serum K levels in patients at risk of hyperkalemia especially in the presence of renal impairment &/or heart failure. Increased risk of fatal MI & unexpected CV death in diabetic patients w/ additional CV risk ie, patients w/ DM & coexistent CAD. Undergo appropriate diagnostic evaluation eg, exercise stress testing, to detect & to treat CAD accordingly before initiating treatment in patients w/ DM. Excessive reduction of BP in patients w/ ischemic cardiopathy or ischemic CV disease. May affect ability to drive & use machine. Mild to moderate hepatic impairment. Not recommended during pregnancy (1st trimester) & not to be initiated during pregnancy. Black people. Childn <18 yr.

UTI including cystitis, URTI, sepsis; anemia, eosinophilia, thrombocytopenia; anaphylactic reaction, hypersensitivity; hyperkalemia, hypoglycemia (in diabetic patients); anxiety, insomnia, depression; syncope; visual disturbance; vertigo; bradycardia, tachycardia; hypotension, orthostatic hypotension; dyspnea; abdominal pain, diarrhea, dry mouth, dyspepsia, flatulence, stomach discomfort, vomiting; abnormal hepatic function/liver disorder; pruritus, hyperhidrosis, rash, angioedema (w/ fatal outcome), eczema, erythema, urticaria, drug eruption, toxic skin eruption; back pain, muscle spasms, myalgia, arthralgia, pain in extremity (leg pain), tendon pain (tendinitis like symptoms); renal impairment including renal failure; chest pain, flu-like illness, asthenia; increased blood creatinine, blood uric, hepatic enzymes & blood creatine phosphokinase, decreased Hb.

May increase hypotensive effect of other antihypertensive agents. Increase in median plasma digoxin trough conc. Increased AUC_0-24 & C_max of ramipril & ramiprilat. Reversible increases in serum lithium conc & toxicity. Potential for acute renal insufficiency w/ NSAIDs (ie, ASA at anti-inflammatory dosage regimens, COX-2 inhibitors & nonselective NSAIDs) in patients who are dehydrated. Reduced effect by inhibition of vasodilating prostaglandins w/ NSAIDs. May increase K level w/ K-sparing diuretics, K supplements, salt substitutes containing K, or other medicinal products that may increase K level (eg, heparin).

Angiotensin II Antagonists

C09CA07 - telmisartan ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.

Rx